Navigation Links
LCA-Vision Board of Directors Responds to Recent Letters from Stockholder Group
Date:12/10/2008

CINCINNATI, Dec. 10 /PRNewswire-FirstCall/ -- LCA-Vision Inc. (Nasdaq: LCAV) ("LCA-Vision" or the "Company"), a leading provider of laser vision correction services under the LasikPlus(R) brand, today announced that its Board of Directors has sent a letter to three stockholders in response to recent letters from those stockholders to the Board.

The full text of the letter from the Company's Board of Directors appears below:

                              December 10, 2008

    VIA EMAIL & CERTIFIED MAIL

    Stephen N. Joffe
    Craig P. Joffe
    Alan H. Buckey
    9650 Montgomery Road
    Cincinnati, Ohio 45242

    Gentlemen:

The Board of Directors of LCA-Vision has received and reviewed each of your letters.

The Board is, of course, concerned about the Company's recent operating results and aware of the business challenges the Company faces, although it does not agree with your description of the Company's condition as "dire" or its prognosis as "poor." As in prior economic downturns, a decline in consumer confidence and discretionary spending has adversely affected the Company's performance. The Company has adopted and is implementing a business plan, including the actions described in its recent SEC filings, which the Board believes are appropriate during the current difficult economic situation. The Board is confident in the ability of its current management team to execute this business plan.

With respect to your recent request for Board representation and appointment to management positions at the Company, as you have noted repeatedly, each of you has previously served as an executive officer of LCA- Vision and, in the case of Steve and Craig, also as a Director. Each of you voluntarily resigned from those positions of trust to pursue alternative person
'/>"/>

SOURCE LCA-Vision Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine news :

1. LCA-Visions Former Executive Management Urge Board of Directors to Immediately Call Special Shareholder Meeting to Approve Poison Pill
2. 11.4% Shareholders & Former Executive Management of LCA-Vision Seek Board Representation and Executive Management Positions
3. LCA-Vision to Present at RBC Capital Markets 2008 Healthcare Conference
4. 11.4% Shareholders & Former Executive Management of LCA-Vision Express Shock and Disbelief at Recent Adoption of Poison Pill
5. LCA-Vision Adopts Stockholder Rights Plan
6. Founders & Former Executive Management Team of LCA-Vision Seek Change to Rescue Company
7. LCA-Vision to Present at the Rodman & Renshaw 10th Annual Healthcare Conference
8. LCA-Vision Reports Third Quarter 2008 Financial Results
9. LCA-Vision Named Provider for New Insured Lasik Product
10. LCA-Vision Announces Upcoming Investment Community Events
11. LCA-Vision Provides Business Update and Market Review
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/4/2009)NEW YORK, Dec. 4 Care Investment Trust Inc. (NYSE: CRE ) ("Care" or the "Company") today announced that its Board of Directors has declared a dividend of $0.17 per share of common stock. The div
(Date:12/4/2009)PEMBROKE, Bermuda, Dec. 4 Allied World Assurance,Company Holdings, Ltd (NYSE: AWH ) today announced that Scott Carmilani,President and Chief Executive Officer, and Jack Sennott, Executive Vice,Pres
(Date:12/4/2009)KANSAS CITY, Mo., Dec. 4 The large, two-day free health clinic sponsored by the National Association of Free Clinics (NAFC) in Kansas City on Wednesday and Thursday is not just for the sick but also
(Date:12/4/2009)WASHINGTON, Dec. 4 While Congress debates whether health care reform would control health care costs, Leapfrog,s purchaser members point to 45 hospitals that lead through example -- delivering the be
(Date:12/4/2009)STANFORD, Calif. A new study shows that muscle cells grown in the lab can restore an intestine,s ability to squeeze shut properly. The work, performed in dogs and rats, might ultimately help treat pa
Breaking Medicine News(10 mins):Health News:Care Investment Trust Inc. Declares Quarterly Dividend of $0.17 Per Share 2Health News:Allied World to Present at the 2009 Goldman Sachs U.S. Financial Services Conference 2Health News:Free Health Clinic Event Is Not Just for the Sick 2Health News:The Leapfrog Group Releases Its 2009 Top Hospitals List 2Health News:The Leapfrog Group Releases Its 2009 Top Hospitals List 3Health News:Muscle cell infusion shown to strengthen sphincters in animals in Stanford study 2Health News:Muscle cell infusion shown to strengthen sphincters in animals in Stanford study 3Health News:Muscle cell infusion shown to strengthen sphincters in animals in Stanford study 4
...s today filed an appeal in their challenge of a co...eld by the Wisconsin Alumni Research,Foundation (W... for Taxpayer and Consumer,Rights, and the Public ...s requested a re-examination of the patent,in July...
...nnipeg (July 18, 2008) Funding of $4.4 million fr...R) was announced today by Steven Fletcher, MP for ... Secretary for Health, on behalf of Tony Clement, ...Health Commission of Canada is contributing $250,0...
...chigan State University scholar refutes commonly h..., more emotionally unstable and harder to get alon...ith the findings, employers are urged to guard aga...ent, and two colleagues studied the relationship b...
...paign to raise awareness, of the importance of t... compliance rates across the United St...ation, a,nonprofit organization dedicated to healt...ay, July 19 in conjunction,with the Ebenezer Afric...
...eld,United Concordia Companies, Inc. and Catholic ...es and lifestyles for Pittsburghers. Beginning at ...y 19, a free clinic will,offer health information ...re than other aspects of health care. The percepti...
...t old drug offers new hope , , FRIDAY, Jul...ne step back in the search for treatments against ...e July 19 issue of The Lancet , an older drug cal...er,s -- even though it cleared dementia-linked amy...
Other Medicine News:Health News:Consumer Groups File Appeal on Challenge of Human Stem Cell Patent Held By WARF 2Health News:CIHR announces $4.4 million to improve mental health of Canadians 2Health News:Studies refute common stereotypes about obese workers 2Health News:The COSHAR Foundation Participates in Annual Women's Health Awareness Day 2Health News:The COSHAR Foundation Participates in Annual Women's Health Awareness Day 3Health News:Highmark Blue Cross Blue Shield, United Concordia and Catholic Charities Join Forces to Offer Free Health, Dental Services This Saturday 2Health News:Alzheimer's Research Brings Progress, Setbacks 2Health News:Alzheimer's Research Brings Progress, Setbacks 3Health News:Alzheimer's Research Brings Progress, Setbacks 4
(Date:12/4/2009)BETHESDA, Md., Dec. 4 Drs. Neal Shore and E. David Crawford presented results for prostate-specific antigen (PSA) recurrence from the additional analysis of secondary end points of biochemical recurr
(Date:12/4/2009)WILMINGTON, Del., Dec. 4 AstraZeneca (NYSE: AZN ) today announced that the US Food and Drug Administration (FDA) has approved once-daily SEROQUEL XR® (quetiapine fumarate) Extended Release Tab
(Date:12/3/2009)NEW YORK, Dec. 3 Guidepoint Global, LLC , a leading primary research firm, today announced the launch of their Sleep Apnea Tracker, a monthly longitudinal data release that monitors and projects tre
Breaking Medicine Technology:Degarelix (FIRMAGON(R)) vs Leuprolide (Lupron Depot(R)) in Patients With Advanced Prostate Cancer: Further Analysis From a Phase III Pivotal Trial 2Degarelix (FIRMAGON(R)) vs Leuprolide (Lupron Depot(R)) in Patients With Advanced Prostate Cancer: Further Analysis From a Phase III Pivotal Trial 3Degarelix (FIRMAGON(R)) vs Leuprolide (Lupron Depot(R)) in Patients With Advanced Prostate Cancer: Further Analysis From a Phase III Pivotal Trial 4US FDA Approves SEROQUEL XR(R) For Add-On Treatment of Major Depressive Disorder 2US FDA Approves SEROQUEL XR(R) For Add-On Treatment of Major Depressive Disorder 3US FDA Approves SEROQUEL XR(R) For Add-On Treatment of Major Depressive Disorder 4US FDA Approves SEROQUEL XR(R) For Add-On Treatment of Major Depressive Disorder 5US FDA Approves SEROQUEL XR(R) For Add-On Treatment of Major Depressive Disorder 6US FDA Approves SEROQUEL XR(R) For Add-On Treatment of Major Depressive Disorder 7US FDA Approves SEROQUEL XR(R) For Add-On Treatment of Major Depressive Disorder 8US FDA Approves SEROQUEL XR(R) For Add-On Treatment of Major Depressive Disorder 9Leading Primary Research Firm Guidepoint Global Announces Launch of Sleep Apnea Tracker 2Cepheid Receives Grant to Develop Ten Color Real Time PCR Detection Technology for Use in the GeneXpert 28R 29 System 4584 1Cepheid Receives Grant to Develop Ten Color Real Time PCR Detection Technology for Use in the GeneXpert 28R 29 System 4584 2Cepheid Receives Grant to Develop Ten Color Real Time PCR Detection Technology for Use in the GeneXpert 28R 29 System 4584 3Cepheid Receives Grant to Develop Ten Color Real Time PCR Detection Technology for Use in the GeneXpert 28R 29 System 4584 4Brain computer interface developed at Brown begins new clinical trial 8783 1Brain computer interface developed at Brown begins new clinical trial 8783 2Brain computer interface developed at Brown begins new clinical trial 8783 3Brain computer interface developed at Brown begins new clinical trial 8783 4Watson Files FDA Application for Generic Mucinex 28R 29 D 48412 1Watson Files FDA Application for Generic Mucinex 28R 29 D 48412 2Watson Files FDA Application for Generic Mucinex 28R 29 D 48412 3
...LANTA, July 7 GeoVax Labs, Inc. (OTC,Bulletin Boa...armaceutical,company specializing in the preventio...ided an operational update on the company,s progre...nical trial testing and,plans to proceed into ther...uccessful human trials evaluating GeoVax AIDS vacc...
... GeneOhm(TM) Cdiff Assay Submitted for FDA Clearan...of BD (Becton, Dickinson and Company) (NYSE: BDX ...m(TM) Cdiff molecular assay for the rapid diagnosi... (CDI). It is the first CDI,diagnostic test that o...t,procedure. BD has also submitted this assay to t...
Other Medicine Technology:GeoVax Reports Progress on Its AIDS Vaccine Technology 2GeoVax Reports Progress on Its AIDS Vaccine Technology 3GeoVax Reports Progress on Its AIDS Vaccine Technology 4GeoVax Reports Progress on Its AIDS Vaccine Technology 5BD Announces CE Marking of a New Molecular Test to Diagnose Patients with Clostridium difficile Infections 2BD Announces CE Marking of a New Molecular Test to Diagnose Patients with Clostridium difficile Infections 3
Creatine Kinase (CK-NAC)
Alanine Aminotransferase (ALT) GPT
Alkaline Phosphatase (ALP) (DIMENSION)
...ost other EMR,systems require you to,change th...c patient charting,solution designed to fit into...round,five specific criteria to,enhance overal...oPad allows you to see,more patients in the same...
Medicine Products: